HK Stock Market Move | CSTONE PHARMA-B(02616) rose more than 3% in early trading, and the Pratinib capsules were included in the 2025 national medical insurance catalog.

CSTONE PHARMA-B (02616) rose more than 3% in the morning session, with an increase of 2.51% as of the time of writing, reaching 5.71 Hong Kong dollars, with a trading volume of 7.2904 million Hong Kong dollars. On the news front, on December 8th, CSTONE PHARMA-B announced that its Piguwa (Pralsetinib capsules, 100 mg) has been included in the latest version of the National Health Security Administration's drug list for basic medical insurance, maternity insurance, and work-related injury insurance in China, which will be officially implemented on January 1, 2026. Piguwa was developed by Blueprint Medicines, a partner of CSTONE PHARMA-B (which was acquired by Sanofi in July 2025). CSTONE PHARMA-B has exclusive development and commercialization rights for Piguwa in the Greater China region (including mainland China, Hong Kong, Macau, and Taiwan). In November 2023, CSTONE PHARMA-B granted Shanghai Allist Pharmaceuticals Co., Ltd., exclusive commercialization promotion rights for Piguwa in mainland China.